Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment

Journal of Clinical Psychiatry

Volumn 78, Issue 8, 2017, Pages 1136-1147

  Correll, Christoph U ^a   Kane, John M ^a   Citrome, Leslie L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMANTADINE; ANTIPARKINSON AGENT; CLONAZEPAM; CLOZAPINE; DEUTETRABENAZINE; DONEPEZIL; DOPAMINE RECEPTOR BLOCKING AGENT; GINKGO BILOBA EXTRACT; LITHIUM SALT; MELATONIN; NEUROLEPTIC AGENT; PYRIDOXINE; TETRABENAZINE; VALBENAZINE; MUSCLE RELAXANT AGENT; VALINE; VESICULAR MONOAMINE TRANSPORTER;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; AFRICAN AMERICAN; AGE; ALCOHOL ABUSE; ARTICLE; COGNITIVE DEFECT; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG EXPOSURE; DSM-5; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYMPTOM RATING SCALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOOD DISORDER; MOTOR DYSFUNCTION ASSESSMENT; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SEX; SIMPSON DYSKINESIA SCALE; TARDIVE DYSKINESIA; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLASSIFICATION; MEDICATION THERAPY MANAGEMENT;

ANTIPSYCHOTIC AGENTS; HUMANS; LONG TERM ADVERSE EFFECTS; MEDICATION THERAPY MANAGEMENT; NEUROMUSCULAR AGENTS; TARDIVE DYSKINESIA; TETRABENAZINE; VALINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 85032617005     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.tv17016ah4c     Document Type: Article

References (62)

1. Jankelowitz SK Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat. 2013; 9: 1371-1380.
2. Schonecker M. Paroxysmal dyskinesia as the effect of megaphen. (German) Ner venarzt. 1957; 28 (12): 550-553.
3. Lerner PP, Miodownik C, Lerner V. Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci. 2015; 69(6):321-334.
4. Carbon M, Hsieh C-H, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017; 78 (3):e264-e278.
5. Mehta SH, Morgan JC, Sethi KD. Drug-induced movement disorders. Neurol Clin. 2015; 33 (1): 153-174.
6. Browne S, Roe M, Lane A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskine sia. Acta Ps ychiatr Scand. 1996; 94(2):118-124.
7. Ballesteros J, González-Pinto A, Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven indep endent studies. J Clin Psychopharm acol. 2000; 20(2):188-194.
8. Carton L, Cottencin O, Lapeyre-Mestre M, et al. Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Curr Pharm Des. 2015; 21(23): 3280-3297.
9. Lerner V, Miodownik C. Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? a modern treatment. Curr Psychiatry Re p. 2011; 13(4):295-304.
10. Correll CU, Rubio JM, Inczedy-Farkas G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017; 74(7):675-684.
11. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008; 21(2):151-156.
12. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004; 161(3): 414-425.
13. Woerner MG, Alvir JM, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998; 155 (11):1521-1528.
14. Woerner MG, Correll CU, Alvir JMJ, et al. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naive patients. Neuropsychopharmacology. 2011; 36 (8): 1738-1746.
15. Wonodi I, Adami HM, Cassady SL, et al. Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. J Clin Psychopharmacol. 2004; 24 (6): 592-598.
16. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013; 3: tre-03-161-4138-1.
17. Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol. 2011; 100: 601-616.
18. Zádori D, Veres G, Szalárdy L, et al. Drug-induced movement disorders. Expert Opin Drug Saf. 2015; 14 (6): 877-890.
19. Divac N, Prostran M, Jakovcevski I, et al. Second-generation antipsychotics and extrapyramidal adverse effects. BioMed Res Int. 2014; 2014: 656370.
20. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare; 1976.
21. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. Fifth Edition. Washington, DC: American Psychiatric Association; 2013.
22. Caroff SN, Hurford I, Lybrand J, et al. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011; 29 (1):127-148.
23. Citrome L, Dufresne R, Dyrud JM. Tardive dyskinesia: minimizing risk and improving outcomes in schizophrenia and other disorders. Am J Manag Care. 2007. http://www.ajmc.com/journals/supplement/2007/2007-12-vol12-n1-decisionmakernews/dec07-2760p1-12. Accessed December 20, 2016.
24. Aquino CCH, Lang AE. Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord. 2014; 20(suppl 1):S113-S117.
25. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. A rch Gen Ps ychiatr y. 1982; 39(4): 486-487.
26. Koning JPF, Tenback DE, van Os J, et al. Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta - analysis. Schizophr Bull. 2010; 36 (4): 723-731.
27. Simpson GM, Lee JH, Zoubok B, et al. A rating scale for tardive dyskinesia. Psychopharmacology (Berl). 1979; 64 (2): 171-179.
28. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005; 76(2-3):247-265.
29. Stomski NJ, Morrison P, Meyer A. Antipsychotic medication side effect assessment tools: a systematic review. Aust N Z J Psychiatry. 2016; 50(5):399-409.
30. Bark N, Florida D, Gera N, et al. Evaluation of the routine clinical use of the Brief Psychiatric Rating Scale (BPRS) and the Abnormal Involuntary Movement Scale (AIMS). J Psychiatr Pract. 2011; 17(4):300-303.
31. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004; 161(2 suppl):1-56.
32. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics, part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry. 2005; 50(11):703-714.
33. Roth LS Tarvil for tardive dyskinesia: are we robbing Peter to pay Paul? Fed Pract. 2004; 21(11):48.
34. Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry. 2003; 160 (6): 1117-1124.
35. North America SHS. First medical food treatment for antipsychotic drug-related tardive dyskinesia introduced. PR Newswire. http://www.prnewswire.com/news-releases/first-medical-food-treatment-for-anti-psychotic-drug-related-tardive-dyskinesia-introduced-77571632.html. Published May 22, 2002. Accessed June 15, 2017.
36. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013; 81(5):463-469.
37. Zutshi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov (N Y). 2014; 4:266.
38. Mentzel CL, Bakker PR, van Os J, et al. Effect of antipsychotic type and dose changes on tardive dyskinesia and parkinsonism severity in patients with a serious mental illness: the Curaçao Extrapyramidal Syndromes Study XII. J Clin Psychiatry. 2017; 78 (3):e279-e285.
39. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. N eurotherapeutics. 2014; 11 (1): 166-176.
40. Bobruff A, Gardos G, Tarsy D, et al. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry. 1981; 138 (2):189-193.
41. Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990; 147(4):445-451.
42. Zheng W, Xiang Y-Q, Ng CH, et al. Extract of ginkgo biloba for tardive dyskinesia: meta-analysis of randomized controlled trials. Pharmacopsychiatry. 2016; 49 (3):107-111.
43. Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010; 33(6): 271-275.
44. Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997; 17 (2): 88-91.
45. Leung JG, Breden EL. Tetrabenazine for the treatment of tardive dysk in esia. Ann Pharmacother. 2011; 45(4):525-531.
46. Bernstein AI, Stout KA, Miller GW. The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int. 2014; 73: 89-97.
47. Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia, I: clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry. 1972; 27 (1): 95-99.
48. Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry. 1973; 130(4):479-483.
49. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999; 156 (8):1279-1281.
50. Shen V, Clarence-Smith K, Hunter C, et al. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington's and other dis eas es. Tremor Other Hyperkinet Mov (N Y). 2013; 3.
51. Xenazine (tetrabenazine): highlights of prescribing information. June 2015. https://www.accessdata.fda.gov/drugsatfda-docs/label/2015/021894s010lbl.pdf. Accessed June 16, 2017.
52. Müller T. Valbenazine granted breakthrough drug status for treating tardive dysk inesia. Expert Opin Investig Drugs. 2015; 24 (6):737-742.
53. Meyer JM Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectr. 2016; 21(S1):13-24.
54. Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016; 17(18): 2461-2470.
55. Ingrezza (valbenazine): highlights of prescribing information. April 2017. http://ingrezza.com/HCP/PI. Accessed September 8, 2017.
56. Austedo (deutetrabenazine): highlights of prescribing information. August 2017. https://www.austedo.com/pi. Accessed September 8, 2017.
57. Meyer JM Valbenazine for tardive dyskinesia. Curr Psychiatr. 2017; 16(5):40-46.
58. O'Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015; 30 (12):1681-1687.
59. Hauser RA, Factor SA, Marder SR, et al. Kinect 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017; 174 (5): 476-484.
60. Citrome L. Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017; 71(7):e12964.
61. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology. 2017; 88(21):2003-2010.
62. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017; 4(8):595-604.